Indaptus Therapeutics to Present Positive Data on Lead Product Candidate, Decoy20, at STING & TLR-Targeted Therapies Summit
June 11, 2024 08:00 ET
|
Indaptus Therapeutics
- Chief Scientific Officer Dr. Newman to present initial clinical data that further validates Company’s “Pulse-Prime” hypothesis - Dr. Newman also named Chair of the Summit NEW YORK, June 11, 2024...
Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20
June 03, 2024 08:00 ET
|
Indaptus Therapeutics
Latest data from first and second cohorts support Company’s 'pulse-prime' approach, demonstrating rapid clearance, broad immune activation, and encouraging safety profile Poster Presented at American...
Indaptus Therapeutics to Present New Cohort Data Confirming Original “Pulse-Prime” Hypothesis Via Phase 1 Clinical Trial of Decoy20 at the American Society of Clinical Oncology Annual Meeting
May 29, 2024 08:00 ET
|
Indaptus Therapeutics
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection...
Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company’s Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid Tumors
May 22, 2024 08:00 ET
|
Indaptus Therapeutics
First-in-human trial confirms “Pulse-Prime” hypothesis targeting stimulation of innate and adaptive immune systemsInvestigational package of broad immune agonists derived from Gram-negative bacteria...
Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort
March 04, 2024 07:30 ET
|
Indaptus Therapeutics
• Positive data following completion of second cohort of Phase 1 trial of Decoy 20 leads independent Safety Review Committee to recommend initiating multi-dosing cohort • Single dose cohort data...
Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 06, 2023 16:01 ET
|
Indaptus Therapeutics
NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the third quarter ended September 30, 2023...
Indaptus Therapeutics’ Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 Study
November 06, 2023 08:00 ET
|
Indaptus Therapeutics
NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical biopharma company that utilizes a proprietary killed, non-pathogenic bacteria-based platform to...
Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting
October 31, 2023 09:01 ET
|
Indaptus Therapeutics
Poster to be presented at 38th Annual Meeting of the Society for Immunotherapy of Cancer on November 4, 2023 NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP)...
Indaptus Therapeutics Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20
September 19, 2023 08:00 ET
|
Indaptus Therapeutics
NEW YORK, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) announces dosing of the first patient in the second cohort of patients to...
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update
March 17, 2023 08:00 ET
|
Indaptus Therapeutics
NEW YORK, March 17, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced financial results for the fourth quarter and fiscal year ended...